NCT06820476

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Oral Doses of NNC0487-0111 in Chinese Participants With Overweight or Obesity

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The study is testing a new study medicine called NNC0487-0111 for weight control in Chinese people with Body mass index (BMI) greater than or equal to (\>=) 24 kilogram per square meter (kg/m\^2). The aim of this study is to find out how safe the study medicine is and how it behaves in your body. Participants will either get NNC0487-0111 or placebo. Which treatment participants will get is decided by chance. Oral NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The study will last for about 60 days.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	NNC0487-0111	Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
DRUG	Placebo (NNC0487-0111)	Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.

Timeline

• Start date: 2025-02-09
• Primary completion: 2025-05-14
• Completion: 2025-05-14
• First posted: 2025-02-11
• Last updated: 2025-08-20

Locations

2 sites across 1 country: China